Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
Holding CMRX?
Track your performance easily
CMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.75 - $1.30
Previous Close$0.86
Volume130.64K
Average Volume (3M)481.86K
Market Cap
$77.09M
Enterprise Value-$54.59M
Total Cash (Recent Filing)$132.51M
Total Debt (Recent Filing)$827.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Oct 31, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding89,638,635
10 Day Avg. Volume150,945
30 Day Avg. Volume481,857
Standard Deviation0.22
R-Squared0.07
Alpha-0.00486
Financial Highlights & Ratios
Price to Book (P/B)0.49
Price to Sales (P/S)547.42
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-379.13
Enterprise Value/Gross Profit-168.50
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$7.20Price Target Upside737.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Chimerix News
PremiumCompany Announcements
Chimerix Releases Updated Corporate Presentation for Stakeholders
PremiumPre-Earnings
Chimerix (CMRX) Q2 Earnings Cheat SheetBulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe Phase 3 ACTION study for ONC201 is progressing, with an increasing number of study sites and patient enrollment expected to accelerate.
Financial StabilityChimerix reported better-than-expected 4Q23 earnings per share, surpassing analyst estimates and demonstrating financial stability with a substantial cash reserve.
Regulatory MilestonesONC201 has received Fast Track Designation and Rare Pediatric Disease Designation from the FDA, indicating regulatory support and potential for expedited development.
Bears Say
Clinical Trial UpdatesThe timing for interim overall survival data from the phase 3 trial for ONC201 has been changed, with results now expected in 2025.
EarningsChimerix reported first quarter earnings per share of ($0.25), which was below the estimated ($0.21).
Financial PerformanceCMRX reported a net loss of ($21.9 million) in its first quarter results.
---
Ownership Overview
27.55% Insiders
10.58% Mutual Funds
28.71% Other Institutional Investors
33.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMRX FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was $0.75 and its highest was $1.30 in the past 12 months.
What is Chimerix’s market cap?
Currently, no data Available
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on Aug 13, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.02.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -$0.24.
How many shares outstanding does Chimerix have?
Chimerix has 89,638,630 shares outstanding.
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went down -6.098%.
Which hedge fund is a major shareholder of Chimerix?
Among the largest hedge funds holding Chimerix’s share is RA Capital Management. It holds Chimerix’s shares valued at 8M.
---
Chimerix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (737.21% Upside)
$7.20 (737.21% Upside)
Blogger Sentiment
Bullish
CMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.50%
12-Months-Change
Fundamentals
Return on Equity
-44.62%
Trailing 12-Months
Asset Growth
-25.96%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
---
CMRX Earnings Call
Q2 2024
0:00 / 0:00
---
CMRX Stock 12 Month Forecast
Average Price Target
$7.20
▲(737.21% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Mersana Therapeutics
―
Best Analysts Covering CMRX
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-10.85%
reiterated a buy rating last month
Copying Soumit Roy's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -10.85% per trade.
---